Current and emerging direct oral anticoagulants: State-of-the-art

Medicine and Dentistry

• Antithrombotic 40%
• Antithrombotic Agent 20%
• Antithrombotic Therapy 20%
• Apixaban 20%
• Betrixaban 20%
• Blood Clotting 20%
• Clinical Trial 40%
• Coumarin Derivative 20%
• Dabigatran 20%
• Darexaban 20%
• Direct Oral Anticoagulant 100%
• Diseases 20%
• Drug Interaction 20%
• Edoxaban 20%
• Eribaxaban 20%
• Factor X 20%
• Fidexaban 20%
• Heparin Derivative 20%
• Letaxaban 20%
• N [2 [4 (1 Methyl 4 Piperidinyl) 1 Piperazinyl] 2 Oxo 1 Phenylethyl] 1h Indole 6 Carboxamide 20%
• Odiparcil 20%
• Otamixaban 20%
• Patient Recruitment 20%
• Pharmacodynamics 20%
• Pharmacokinetics 40%
• Rivaroxaban 20%
• Side Effect 20%
• Thrombin 20%
• Thrombosis 20%
• Ximelagatran 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Anticoagulant Agent 60%
• Antithrombotic Therapy 20%
• Apixaban 20%
• Betrixaban 20%
• Blood Clotting Factor 10 20%
• Clinical Trial 40%
• Coumarin Derivative 20%
• Dabigatran 20%
• Darexaban 20%
• Direct Oral Anticoagulant 100%
• Disease 20%
• Drug Interaction 20%
• Edoxaban 20%
• Eribaxaban 20%
• Fidexaban 20%
• Heparin Derivative 20%
• Letaxaban 20%
• N [2 [4 (1 Methyl 4 Piperidinyl) 1 Piperazinyl] 2 Oxo 1 Phenylethyl] 1h Indole 6 Carboxamide 20%
• Odiparcil 20%
• Otamixaban 20%
• Patient Recruitment 20%
• Pharmacodynamics 20%
• Pharmacokinetics 40%
• Rivaroxaban 20%
• Side Effect 20%
• Thrombin 20%
• Thrombosis 20%
• Ximelagatran 20%

Keyphrases

• Multiple Indications 20%
• Odiparcil 20%